How Isoniazid, Rifampicin, and Ethambutol Fight TB

Tuberculosis, commonly known as TB, is a bacterial infection caused by Mycobacterium tuberculosis.The causative agent, Mycobacterium tuberculosis, is a rod-shaped bacterium with a distinctive waxy cell wall that makes it resistant to many antibiotics.TB primarily affects the lungs, causing symptoms like persistent cough, chest pain, and in severe cases, coughing up blood.Tuberculosis remains one of the top infectious disease killers worldwide. According to the World Health Organization, approximately ten million people fall ill with TB annually, primarily in developing countries.The standard treatment for tuberculosis involves a combination of antibiotics. The most important first-line drugs include isoniazid, rifampicin, and ethambutol.Treating tuberculosis poses several significant challenges due to the unique characteristics of Mycobacterium tuberculosis.The first major challenge comes from the bacterium's unique cell wall structure.This cell wall contains mycolic acids, which create a waxy, hydrophobic layer around the bacterium.Due to this impermeable cell wall, many antibiotics cannot penetrate the bacterium, making it naturally resistant to many drugs.The second major challenge is that Mycobacterium tuberculosis can enter a dormant state.In active tuberculosis, bacteria replicate approximately every twenty-four hours.However, in its dormant state, bacteria can slow or completely stop replication, remaining inactive for months or even years.This dormancy presents a significant treatment challenge because many antibiotics target active cellular processes, making them ineffective against dormant bacteria.These challenges necessitate a unique approach to tuberculosis treatment.Because of the complex cell wall and the presence of dormant bacteria, a combination of different drugs is required.Each drug in the regimen targets different aspects of the bacteria. For example, one drug might target the cell wall synthesis.Another might inhibit protein synthesis.And a third could disrupt DNA replication. Using multiple mechanisms of action helps overcome the bacterium's defenses.Another challenge is the duration of treatment. Because of the bacterium's slow growth and dormancy, treatment typically lasts for at least six months.This extended treatment period is necessary to ensure all bacteria are eliminated, including those in dormant states, which helps prevent relapse and the development of drug resistance.Isoniazid, commonly abbreviated as INH, is one of the primary drugs used in tuberculosis treatment.Isoniazid is a prodrug, which means it requires activation within the bacteria before it can exert its antibacterial effects.Mycobacterium tuberculosis is characterized by its unique cell wall containing mycolic acids, which is the target of isoniazid.The bacterial enzyme catalase-peroxidase, known as KatG, is responsible for activating isoniazid within the bacterial cell.In the first step of its mechanism, isoniazid is converted to its active form by KatG, producing reactive species that can inhibit critical enzymes.Once activated, isoniazid specifically targets the enzyme InhA, also known as enoyl-ACP reductase.InhA is a critical enzyme in the fatty acid synthase two system, responsible for producing mycolic acids essential for the bacterial cell wall.When isoniazid inhibits InhA, it disrupts the synthesis of mycolic acids, compromising the integrity of the bacterial cell wall.The inhibition of this pathway leads to accumulation of toxic metabolites inside the bacterial cell, further contributing to its lethal effect.Ultimately, these combined effects lead to bacterial cell death, especially among actively dividing bacteria.Isoniazid is particularly effective against actively dividing mycobacteria, making it a powerful component of TB treatment regimens.This selective action against actively dividing bacteria explains why isoniazid is a key component in tuberculosis treatment regimens.Pharmacokinetics describes how drugs move through the body. This includes absorption, distribution, metabolism, and excretion.Let's examine the pharmacokinetic profiles of the three main TB drugs: Isoniazid, Rifampicin, and Ethambutol.Isoniazid is rapidly absorbed from the gastrointestinal tract and widely distributed throughout the body. It can penetrate the blood-brain barrier, reaching therapeutic concentrations in the cerebrospinal fluid.Rifampicin is well absorbed orally and widely distributed in tissues. Importantly, it induces liver enzymes, particularly cytochrome P450, which can significantly affect the metabolism of many other drugs.Ethambutol is less well absorbed compared to isoniazid and rifampicin. It has moderate tissue distribution but doesn't penetrate the cerebrospinal fluid effectively, limiting its use for TB meningitis.All three drugs are typically administered orally once daily. The standard regimen includes isoniazid, rifampicin, and ethambutol, often with pyrazinamide during the intensive phase of treatment.Fixed-dose combinations are preferred to improve patient adherence. These tablets combine multiple drugs in a single pill, reducing the number of tablets patients need to take.Dosing is typically weight-based. Isoniazid is given at 5 milligrams per kilogram daily, rifampicin at 10 milligrams per kilogram, and ethambutol at 15 to 20 milligrams per kilogram. All doses are adjusted for patients weighing above 50 kilograms.For optimal absorption, TB drugs should be taken on an empty stomach. All doses should be administered together, and directly observed therapy is often recommended to ensure adherence throughout the 6 to 9 month treatment period.